- Email: [email protected]
5017383 Method of producing fine coated pharmaceutical preparation
New Patents
Xvi
rier. A typical formulation contains about 2.2% of erythromycin, about 8% of octyl pdimethylaminobenzoate, and about 6% of 2hydroxy-4-methoxybenzophenone in a mixture of about 3.8% hydroxypropylcellulose in ethanol.
of a rotating spiral gas flow. A holder (A) containing the mouldings is provided with gas inlets (3). A gas flow through the gas inlet (3) brings the mouldings in a spiral rotating movement in a sphere (C) placed on holder (A). Coating material is sprayed in the apparatus by a tube (D), oscillated by the gas flow, on the whirling mouldings.
5017383 METHOD OF PRODUCING FINE COATED PHARMACEUTICAL PREPARATION Yasuo Ozawa, Ikuo Shimano, Ageo, Japan Pharmaceutical Co Ltd
Koyama, assigned
Kimihide to Taisho
A method of producing a fine coated pharmaceutical preparation, which includes cooling fine liquid droplets composed of a liquid medium, a drug dissolved or suspended in the liquid medium, and as required, a binder to a temperature of not higher than the freezing point of the liquid medium to form frozen particles of the drug and as required the binder, adjusting the particle sizes of the fine frozen particles, mixing the fine frozen particles with a fine powder of a coating material having a particle diameter smaller than the particles at a temperature higher than the freezing point of the liquid medium to cause the fine powder of the coating material to adhere to the surfaces of the particles, and then removing the liquid medium from the resulting coated particles.
5017564 SOLID PHARMACEUTICAL PREPARATION AND METHOD OF PRODUCING SAME Tadash Makino, Koji Doi, Masayoshi Matsuoka, Toshiharu Tsuboi, Ibaraki, Japan assigned to Senju Pharmaceutical Co Ltd Provided are a solid pharmaceutical preparation which contains disodium adenosine triphosphate together with a vitamin Bl salt or the like and a method of treatment of human asthenopia by orally administering the same. Also provided are a solid pharmceutical preparation according to the abovementioned preparation, which further contains a low-melting fat- or oil-like substance and has an improved stability of disodium adenosine triphosphate, and a method of producing the same.
5017593
5017401 METHOD AND ARRANGEMENT AND METHOD FOR THE MANUFACTURING OF COATED MOULDINGS, IN PARTICULAR OF CAPSULES CONTAINING PHARMACEUTICAL MATERIALS AND ARE MEANT TO BE USED AS MEDICINE Johannes R van Drunen, The Hague, Netherlands Method and apparatus for coating mouldings consisting of fluidizing the mouldings by means
CYCLOHEPT (B) INDOLEALKANOIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USE John Gillard, Yvan Guindon, Howard E Morton, Yves Girard, Christiane Yoakim, Baie d’Urfe, Canada assigned to Merck Frosst Canada Inc Cyclohept(b)indolealkanoic acids and acid derivatives are disclosed. The compounds act as prostaglandin and thromboxane antagonists and are useful in treating asthma, diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea and nephrotoxicity caused by cyclosporin A and as cytoprotective agents.
Xvi
rier. A typical formulation contains about 2.2% of erythromycin, about 8% of octyl pdimethylaminobenzoate, and about 6% of 2hydroxy-4-methoxybenzophenone in a mixture of about 3.8% hydroxypropylcellulose in ethanol.
of a rotating spiral gas flow. A holder (A) containing the mouldings is provided with gas inlets (3). A gas flow through the gas inlet (3) brings the mouldings in a spiral rotating movement in a sphere (C) placed on holder (A). Coating material is sprayed in the apparatus by a tube (D), oscillated by the gas flow, on the whirling mouldings.
5017383 METHOD OF PRODUCING FINE COATED PHARMACEUTICAL PREPARATION Yasuo Ozawa, Ikuo Shimano, Ageo, Japan Pharmaceutical Co Ltd
Koyama, assigned
Kimihide to Taisho
A method of producing a fine coated pharmaceutical preparation, which includes cooling fine liquid droplets composed of a liquid medium, a drug dissolved or suspended in the liquid medium, and as required, a binder to a temperature of not higher than the freezing point of the liquid medium to form frozen particles of the drug and as required the binder, adjusting the particle sizes of the fine frozen particles, mixing the fine frozen particles with a fine powder of a coating material having a particle diameter smaller than the particles at a temperature higher than the freezing point of the liquid medium to cause the fine powder of the coating material to adhere to the surfaces of the particles, and then removing the liquid medium from the resulting coated particles.
5017564 SOLID PHARMACEUTICAL PREPARATION AND METHOD OF PRODUCING SAME Tadash Makino, Koji Doi, Masayoshi Matsuoka, Toshiharu Tsuboi, Ibaraki, Japan assigned to Senju Pharmaceutical Co Ltd Provided are a solid pharmaceutical preparation which contains disodium adenosine triphosphate together with a vitamin Bl salt or the like and a method of treatment of human asthenopia by orally administering the same. Also provided are a solid pharmceutical preparation according to the abovementioned preparation, which further contains a low-melting fat- or oil-like substance and has an improved stability of disodium adenosine triphosphate, and a method of producing the same.
5017593
5017401 METHOD AND ARRANGEMENT AND METHOD FOR THE MANUFACTURING OF COATED MOULDINGS, IN PARTICULAR OF CAPSULES CONTAINING PHARMACEUTICAL MATERIALS AND ARE MEANT TO BE USED AS MEDICINE Johannes R van Drunen, The Hague, Netherlands Method and apparatus for coating mouldings consisting of fluidizing the mouldings by means
CYCLOHEPT (B) INDOLEALKANOIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USE John Gillard, Yvan Guindon, Howard E Morton, Yves Girard, Christiane Yoakim, Baie d’Urfe, Canada assigned to Merck Frosst Canada Inc Cyclohept(b)indolealkanoic acids and acid derivatives are disclosed. The compounds act as prostaglandin and thromboxane antagonists and are useful in treating asthma, diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea and nephrotoxicity caused by cyclosporin A and as cytoprotective agents.